Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Bronchitis, Sinusitis, Urinary Tract Infections
Interventions: Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Healthy
Interventions: PH-797804, Moxifloxacin, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania

Conditions: Healthy
Interventions: Dapagliflozin, Moxifloxacin, Placebo to match moxifloxacin and dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacterial Infections
Interventions: Ciprofloxacin single dose, Ciprofloxacin triple dose; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: Healthy
Interventions: Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Community-Acquired Bacterial Pneumonia
Interventions: Levofloxacin, CEM-101; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions: Aripiprazole; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Healthy
Interventions: Talampanel, Moxifloxacin, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Schizophrenia
Interventions: Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 39
States / cities: Cerritos, California • Escondido, California • Garden Grove, California + 31 more

Conditions: Fragile X Syndrome
Interventions: Aripiprazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pharmacokinetics
Interventions: Colchicine, Moxifloxacin; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Amphetamine-Related Disorders
Interventions: Aripiprazole; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Schizophrenia, Alzheimer's Disease, Dementia
Interventions: Aripiprazole, Olanzapine, Risperidone; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Microbiota, Anti-bacterial Agents
Interventions: Levofloxacin, Azithromycin, Cefpodoxime; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Otitis Media in Patients With Tympanostomy Tubes
Interventions: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more

Conditions: Kidney Stones
Interventions: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more

Conditions: Keratoconus, Ectasia, Degeneration
Interventions: Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.); Drug
Lead sponsor: Cxlusa; Industry
Eligibility: 8 Years and older
Enrollment: 1,189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 3
States / cities: Miami, Florida • Rockville, Maryland • Fairfax, Virginia

Conditions: Weight Gain, Autism Spectrum Disorder, Medication Side Effect
Interventions: Comparison of Risperidone and Aripiprazole; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Overweight, Obesity
Interventions: Maridebart Cafraglutide, Moxifloxacin, Placebo for Maridebart Cafraglutide, Placebo for Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Autistic Disorder
Interventions: Aripiprazole, Placebo, D-cycloserine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bipolar I Disorder
Interventions: Injectable Risperidone (Consta) or oral antipsychotic; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more

Conditions: Schizophrenia
Interventions: Aripiprazole, placebo; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bacillus Anthracis (Anthrax)
Interventions: Ciprofloxacin 500 mg, ETI-204 (Anthim); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Fluoroquinolone Associated Disability

A Study to Investigate the Effect of PH-797804 on QTc Interval

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Effects of Single Oral Dose Dapagliflozin QT Study

BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

The Effects of Aripiprazole on Patients With Metabolic Syndrome

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

Side Effects of Newer Antipsychotics in Older Adults

Healthy Patients & Effect of Antibiotics

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Struvite Stones Antibiotic Study

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

Risperdal Consta for Bipolar Disorder

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Monoclonal Antibody for Treatment of Inhalation Anthrax